This is the web version of ASH in 30 Seconds, STAT’s report from the American Society of Hematology meeting.
And on the last day of ASH, the sun shone once again. Thanks for joining us on this hematology-oncology journey. We hope you’ve enjoyed our coverage. Until next year, in New Orleans!
J&J’s ‘Tec-Dara’ combo shines in multiple myeloma study
A two-drug regimen from Johnson & Johnson showed an unprecedented tumor-progression benefit compared to the standard of care for patients with relapsed or refractory multiple myeloma, according to results from a Phase 3 study presented today.
